Alpine Global Management’s PAVmed PAVM Stock Holding History

Alpine Global Management’s Portfolio PAVM Stock Details PAVM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-110	Closed	-$122K	–	646
2021 Q4	$122K	Buy	+110	New	+$239K	0.02%	615

Other funds holding PAVM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's PAVM Position: Q1 2022 in Review

Alpine Global Management sold out of PAVmed (PAVM) in Q1 2022, closing a stake of 110 shares — an estimated $122K sold.

Alpine Global Management first reported a position in PAVM in Q4 2021 and held it in 1 quarter. The position peaked at $122K in Q4 2021. 94 funds tracked by Wall St. Rank hold PAVM as of Q1 2022.

Alpine Global Management reported no remaining PAVmed position as of Q1 2022 after selling out during the quarter.
Alpine Global Management sold 110 PAVmed shares in Q1 2022, an estimated $122K.
Alpine Global Management first reported a position in PAVmed in Q4 2021 and held it in 1 quarter.
Alpine Global Management's PAVmed position peaked at $122K in Q4 2021.
94 funds tracked by Wall St. Rank held PAVmed as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.